isatin has been researched along with su 11248 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fales, HM; Gottesman, MM; Hall, MD; Hellawell, JL; Hibbs, DE; Kensler, CB; Ludwig, JA; Salam, NK; Szakács, G | 1 |
| Abdel-Samii, ZKM; Abdelnaser, A; Al-Mahmoudy, AMM; Bekheit, MS; Fayad, W; Girgis, AS; Ibrahim, TS; Nasr, S; Panda, SS; Said, MF; Sakhuja, R; Seliem, IA; Soliman, AAF; Tran, QL | 1 |
2 other study(ies) available for isatin and su 11248
| Article | Year |
|---|---|
Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Death; Cytotoxins; Drug Resistance, Multiple; Enzyme Inhibitors; HeLa Cells; Humans; Hydrophobic and Hydrophilic Interactions; Indoles; Isatin; Quantitative Structure-Activity Relationship; Substrate Specificity | 2009 |
Development of Isatin-Based Schiff Bases Targeting VEGFR-2 Inhibition: Synthesis, Characterization, Antiproliferative Properties, and QSAR Studies.
Topics: Antineoplastic Agents; Fluorouracil; Humans; Isatin; Quantitative Structure-Activity Relationship; Schiff Bases; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2022 |